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An abnormally high serum phosphate level induces calciﬁc aortic stenosis (CAS), which is character-
ized by ectopic valve calciﬁcation and stenosis of the oriﬁce area. Inhibition of ectopic calciﬁcation is a
critical function of any internal medical therapy for CAS disease. The aim of the present study was to
investigate the inhibitory effects of several derivatives of evocarpine, methanolic extracts from the
fruits of Evodia rutaecarpa Bentham (Japanese name: Go-Shu-Yu) on the high phosphate-induced
calciﬁcation of human aortic valve interstitial cells (HAVICs) obtained from patients with CAS. High
phosphate (3.2 mM) concentrations signiﬁcantly increased the calciﬁcation of HAVICs after 7 days of
culture. This calciﬁcation was completely inhibited in the presence of sodium phosphonoformate
(PFA), a selective inhibitor of the type III sodium-dependent phosphate cotransporter (PiT-1). PiT-1
contributes to phosphate uptake, resulting in calciﬁcation. 1-Methyl-2-undecyl-4(1H)-quinolone
(MUQ; 30e300 nM), but not evocarpine or its derivatives dihydroevocarpine and 1-methyl-2-nonyl-
4(1H)-quinolone, inhibited the high phosphate-induced HAVICs calciﬁcation in a concentration-
dependent manner. Although all of the evocarpine derivatives attenuated alkaline phosphatase ac-
tivity, only MUQ also decreased PiT-1 gene expression with cellular PiT-1 protein diminution. These
results suggest that MUQ mitigated high phosphate-induced HAVICs calciﬁcation by inhibiting PiT-1
gene expression.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Calciﬁc aortic valve stenosis (CAS) is the most frequent heart
valve disease in the elderly (1). Aortic valves from patients with CAS
are characterized bymassive ﬁbrotic thickening of the valve leaﬂets
and extensive focal ectopic calciﬁcation (2). Because the irrevers-
ible aortic valve calciﬁcation that occurs in CAS limits the internalurukawa).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).treatment options, themost viable treatment is surgical aortic valve
replacement, which is an extremely invasive procedure (3).
Although several research groups have examined themechanism of
aortic valve calciﬁcation in CAS (4,5), no effective drug target for
preventing the disease has been found, and no effective non-
invasive treatment has been established.
CAS is an active process that may be correlated with several
inﬂammatory factors (6). Inﬂammation is a prominent feature of
aortic valve ectopic calciﬁcation and can be caused by endothelial
dysfunction induced by atherosclerotic risk factors (7). Macro-
phages and T lymphocytes (8,9) release cytokines, such as trans-
forming growth factor-b1 (10) and interleukin-1 (11), both ofnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
K. Seya et al. / Journal of Pharmacological Sciences 131 (2016) 51e5752which contribute to extracellular matrix formation, remodeling,
and ectopic calciﬁcation. Recently, we demonstrated that tumor
necrosis factor-a (TNF-a) also accelerates the calciﬁcation of
aortic valves via the bone morphogenetic protein 2 (BMP2)-Dlx5
axis (12).
In addition to cytokines, abnormally high phosphate levels also
appear to play an essential role in the process of ectopic calciﬁ-
cation (13). Patients with chronic kidney disease (CKD), who have
a hugely elevated risk of cardiovascular mortality compared with
age-matched controls, show accelerated medial and intimal
calciﬁcation, and this calciﬁcation rapidly progresses in patients
on dialysis. The development of calciﬁcation in CKD patients is
strongly linked to their dysregulated mineral metabolism, which
is characterized by the long-term elevation of serum phosphate
levels, as well as transient bouts of hypercalcemia (14). Recently,
we demonstrated that high phosphate (3.2 mM) concentrations
induced calciﬁcation in human aortic valve interstitial cells
(HAVICs) at the cellular level (15). In addition to aging, hyper-
phosphatemia in CKD and dialyzed patients is a major risk factor
for CAS. Thus, the development of new medical drugs that inhibit
the calciﬁcation induced by hyperphosphatemia is eagerly awai-
ted (16).
The quinolone alkaloid evocarpine, 1-methyl-2-[(Z)-8-
tridecene-1-yl]-quinoline-4(1H)-one (Fig. 1), was ﬁrst isolated
from the fruits of the Evodia rutaecarpa plant (Japanese name:
Go-Shu-Yu) (17). The dried fruits of E. rutaecarpa have been used
for a long time in traditional Chinese medical practices for
abdominal pain, dysentery, headache, and amenorrhea (18). This
fruit has also been reported to have a transient hypertensive
effect (19) and positive inotropic and chronotropic effects (20).
Although there are several reports detailing the cardiovascular
effects of evocarpine, the pharmacological effects of evocarpine
and its derivatives on aortic valve ectopic calciﬁcation are still
unclear.
The aim of the present study was to determine whether the
methanolic extracts, evocarpine and its derivatives, from the fruits
of E. rutaecarpa inhibit high phosphate-induced HAVIC calciﬁca-
tion as a ﬁrst step in the development of effective inhibitors for
hyperphosphatemia-induced ectopic calciﬁcation of the aortic
valve. The results show that 1-methyl-2-undecyl-4(1H)-quino-
lone (MUQ), but not evocarpine or the other derivatives, suc-
cessfully inhibited HAVICs calciﬁcation by decreasing the gene
expression of the type III sodium-dependent phosphate cotrans-
porter (PiT-1).1-m
1-m
O
N
CH3
CH3
Dihydroevocarpine
O
N
CH3
CH3Evocarpine
Fig. 1. Chemical structure of evocarpine and its derivatives. All of the compounds have a
includes a 2-tridecyl group, 1-methyl-2-undecyl-4(1H)-quinolone (MUQ) includes a 2-unde2. Materials and methods
2.1. Materials
Penicillin, a-minimal essential medium (a-MEM), and strepto-
mycin were purchased from Life Technologies (Grand Island, NY,
USA). Fetal bovine serum (FBS) was obtained from Nichirei Bio-
sciences (Tokyo, Japan). The other analytical grade chemicals were
obtained from Wako Pure Chemicals (Osaka, Japan). All of the
chemicals used were of the highest purity commercially available.
All of the chemicals were made fresh at sufﬁciently high concen-
trations such that only very small aliquots were added to the assay
tubes or culture media. The ﬁnal concentration of DMSO in the
experimental tubes never exceeded 0.1% and had no effect on the
cells or assays.
2.2. Isolation of evocarpine and its derivatives
The fruits (5 kg) of an E. rutaecarpa, which was purchased from
Kinokuniya-kanyakkyoku Co., Ltd. (Tokyo, Japan), were extracted
three times with methanol (20 L) at room temperature. The extract
was then partitioned with ethyl acetate and water to obtain the
ethyl acetate solubles (135 g). The ethyl acetate solubles were
applied to a silica gel column for chromatography and were eluted
with hexane-ethyl acetate and ethyl acetate-methanol solutions of
increasing polarity to create fraction A (hexane-ethyl acetate (1:1)
eluent, 6.34 g). Fraction A was further separated on a silica gel
column using the chloroformemethanol solvent system to produce
evocarpine (205 mg) and fraction B (chloroformemethanol (39:1)
eluent, 162 mg). Fraction B was separated on an octadecyl-silica
column using the water-acetonitrile solvent system to give 1-
methyl-2-nonyl-4(1H)-quinolone (MNQ, 22 mg), 1-methyl-2-
undecyl-4(1H)-quinolone (MUQ; 63 mg), and dihydroevocarpine
(32 mg). The structures of these isolated compounds are shown in
Fig. 1.
Data for evocarpine: colorless amorphous solid; 1H NMR
(400 MHz, CDCl3) d 8.44 (1H, dd, J ¼ 8.0, 1.7 Hz), 7.64 (1H, ddd,
J ¼ 8.7, 7.0, 1.7 Hz), 7.49 (1H, dd, J ¼ 8.7, 0.9 Hz), 7.25 (1H, ddd,
J¼ 8.0, 7.0, 0.9 Hz), 6.21 (1H, s), 5.30e5.40 (2H, m), 3.72 (3H, s), 2.69
(2H, t, J ¼ 7.8 Hz), 2.01e2.05 (4H, m), 1.67 (2H, quint, J ¼ 7.9 Hz),
1.40e1.45 (2H, m), 1.25e1.36 (10H, m), 0.89 (3H, t, J ¼ 7.1 Hz); EIMS
m/z 339 [M]þ (29%), 310 (36%), 186 (96%), 173 (100%).
Data for 1-methyl-2-undecyl-4(1H)-quinolone (MUQ): colorless
amorphous solid; 1H NMR (400 MHz, CDCl3) d 8.45 (1H, dd, J ¼ 8.0,O
N
CH3
CH3
ethyl-2-undecyl-4(1H)-quinolone 
(MUQ)
O
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CH3
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quinolone structure. Evocarpine includes a 2-tridecylidene group, dihydroevocarpine
cyl group, and 1-methyl-2-nonyl-4(1H)-quinolone (MNQ) includes a 2-nonyl group.
Table 1
Primers used for the quantitative real-time PCR.
Gene symbol Genbank accession no. Sequences (50-30)
ALP NM_000478 Forward: agaaccccaaaggcttcttc
Reverse: cttggcttttccttcatggt
BMP2 NM_001200 Forward: cggactgcggtctcctaa
Reverse: ggaagcagcaacgctagaag
PiT-1 NM_005415 Forward: gatgtcttggttcgtgtccc
Reverse: ggaactggatctgccttatgga
G3PDH NM_002046 Forward: tgcaccaccaactgcttagc
Reverse: ggcatggactgtggtcatgag
K. Seya et al. / Journal of Pharmacological Sciences 131 (2016) 51e57 531.7 Hz), 7.66 (1H, ddd, J ¼ 8.7, 7.0, 1.7 Hz), 7.49 (1H, dd, J ¼ 8.7,
0.9 Hz), 7.35 (1H, ddd, J ¼ 8.0, 7.0, 0.9 Hz), 6.24 (1H, s), 3.74 (3H, s),
2.71 (2H, t, J¼ 7.8 Hz), 1.68 (2H, quint, J¼ 7.7 Hz),1.39e1.44 (2H, m),
1.20e1.36 (14H, m), 0.88 (3H, t, J¼ 7.1 Hz); EIMSm/z 313 [M]þ (17%),
186 (75%), 173 (100%).
Data for dihydroevocarpine: colorless amorphous solid; 1H NMR
(400 MHz, CDCl3) d 8.45 (1H, dd, J ¼ 8.0, 1.7 Hz), 7.66 (1H, ddd,
J ¼ 8.7, 7.0, 1.7 Hz), 7.50 (1H, dd, J ¼ 8.7, 0.9 Hz), 7.35 (1H, ddd,
J ¼ 8.0, 7.0, 0.9 Hz), 6.24 (1H, s), 3.74 (3H, s), 2.71 (2H, t, J ¼ 7.8 Hz),
1.68 (2H, quint, J ¼ 7.8 Hz), 1.39e1.46 (2H, m), 1.20e1.37 (18H, m),
0.88 (3H, t, J ¼ 7.0 Hz); EIMS m/z 341 [M]þ (17%), 186 (89%), 173
(100%).
Data for 1-methyl-2-nonyl-4(1H)-quinolone (MNQ): colorless
amorphous solid; 1H NMR (400 MHz, CDCl3) d 8.45 (1H, dd, J ¼ 8.0,
1.7 Hz), 7.67 (1H, ddd, J ¼ 8.7, 7.0, 1.7 Hz), 7.50 (1H, dd, J ¼ 8.7,
0.9 Hz), 7.35 (1H, ddd, J ¼ 8.0, 7.0, 0.9 Hz), 6.24 (1H, s), 3.73 (3H, s),
2.71 (2H, t, J¼ 7.8 Hz),1.68 (2H, quint, J¼ 7.8 Hz), 1.39e1.46 (2H, m),
1.22e1.35 (10H, m), 0.88 (3H, t, J ¼ 7.0 Hz); EIMS m/z 285 [M]þ
(16%), 186 (62%), 173 (100%).
2.3. HAVICs isolation and culture
Calciﬁed aortic valves were obtained from six patients with CAS
undergoing surgical valve replacement at the Hirosaki University
Hospital after obtaining informed consent. The present study was
approved by the institutional review board of Hirosaki University
Hospital. The human aortic valve specimens were gently cut into
pieces 2 ± 1 mm long. The HAVICs were isolated by collagenase
digestion of the aortic valve pieces as previously described (15,21).
The cells were cultured on a plastic dish in a-MEM containing 10%
fetal bovine serum (FBS). The medium was changed every 3 days.
To induce calciﬁcation, after the HAVICs reached conﬂuency,
they were further cultured in the presence or absence of high
phosphate concentrations (3.2 mM) for 7 days.
2.4. Identiﬁcation of calciﬁcation
Calcium precipitation in the HAVICs was assessed by Alizarin
Red S staining (22). Brieﬂy, the matrix was washed with saline and
incubated with 10% buffered formalin for 15 min. After three
washes with puriﬁed water, the cultures were treated with Alizarin
Red S solution at room temperature for 5 min. Excess Alizarin Red S
solutionwas completely washed away using puriﬁedwater to allow
color development. The stained cells were examined under a digital
camera (Nikon, Tokyo, Japan). Subsequently, the Alizarin Red S dye
was released from the extracellular matrix by incubation with
100 mM aqueous cetylpyridinium chloride solution, and the
amount of released dye was quantiﬁed by spectrophotometry at
550 nm (23).
2.5. ALP activity
After the cells were washed twice with phosphate buffered sa-
line, the cellular proteins were solubilized with 0.5% Triton X-100 in
saline and centrifuged. The supernatants were assayed for ALP ac-
tivity using a commercially available kit (Laboassay™ ALP; Wako,
Tokyo, Japan). One unit was deﬁned as the activity producing
1 nmol of p-nitrophenol over 30 min. The supernatant protein
concentrations were determined by Bradford's method. The change
in activity was expressed as a ratio to the basal value on Day 0.
2.6. Gene expression
The total RNAwas isolated from the cells using a QuickGene RNA
cultured cell kit S (Fujiﬁlm, Tokyo, Japan). An aliquot of total RNAwas reverse transcribed to obtain cDNA using random primers. For
real-time polymerase chain reaction (PCR), the cDNAwas ampliﬁed
(ABI PRISM 7000, Life Technologies, Carlsbad, CA) under the
following reaction conditions: 40 cycles of PCR (95 C for 15 s and
then 60 C for 1 min) after an initial denaturation step (95 C for
1 min). The reaction volume was adjusted to 20 mL containing 3 mL
of a 1:4 dilution of the ﬁrst-strand reaction product, 0.6 mL of 10 mM
speciﬁc forward and reverses primers, 0.4 mL of 50 ROX reference
dye, 5.4 mL of pure water, and 10 mL of SYBR qPCR. The primers used
to detect the expression of ALP, BMP2, PiT-1, and glyceraldehyde 3-
phosphate dehydrogenase (G3PDH) were designed in Primer Ex-
press ver. 2.0® (Life Technologies) and their sequences are shown in
Table 1. Ampliﬁcation of the housekeeping gene G3PDH served as a
normalization standard. The real-time PCR data were represented
as cycle threshold (Ct) levels and normalized to the individual
G3PDH control Ct values. The relative gene expression values were
calculated using the 2(-delta delta C(T)) method (24).
2.7. Western blot analysis of PiT-1
After the HAVICs reached conﬂuency, these cells were pre-
treated with or without MUQ (300 nM) for 2 h and subsequently
cultured in the presence or absence of high phosphate concentra-
tions (3.2 mM) for 7 days. Cells were lysed in 20 mM TriseHCl, pH
7.4. After a Bradford protein assay, proteins (each 3 mg) were
resolved by SDS/polyacrylamide gel electrophoresis, separated on
10% SDS-polyacrylamide gels, and transferred to polyvinylidene
diﬂuoride membranes, Immobilon-FL (Millipore Corporation, Bill-
erica, MA). Membranes were incubated with primary antibody
against PiT-1 (mouse monoclonal antibody 1:500, Abcam, UK) or b-
actin (rabbit polyclonal antibody 1:1000, Abcam, UK) and Alexa
Fluor 680 goat anti-mouse or anti-rabbit secondary antibody
(1:1000, Abcam, UK). Proteins were detected using the Odyssey
Imaging System (LI-COR Biosciences, Lincoln, NE).
2.8. Statistical analysis
All statistical analyses were performed in KyPlot 5.0 software
(Kyenslab, Tokyo, Japan). Differences among groups were tested
using ANOVAs with the StudenteNewmaneKeuls post hoc
correction procedure. Values are presented as means ± S.E.M.
p-values less than 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Effects of 1-methyl-2-undecyl-4(1H)-quinolone (MUQ) on high
phosphate-induced calciﬁcation of HAVICs
The HAVICs obtained from patients with calciﬁc aortic valve
stenosis (n¼ 6; age: 64.3 ± 5.6 years) were cultured in the presence
or absence of high inorganic phosphate (3.2 mM) after reaching
conﬂuence. Marked calciﬁcation of the HAVICs occurred in the
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magnitude of calciﬁcation was signiﬁcantly mitigated by sodium
phosphonoformate (PFA) (25), an inhibitor of PiT-1 (Fig. 2A).
Next, we investigated whether evocarpine and its derivatives
inhibited high phosphate-induced HAVICs calciﬁcation. As shown
in Figs. 2B and 3A, MUQ inhibited calciﬁcation in a concentration-
dependent manner (30e300 nM), but evocarpine and the other
derivatives did not inhibit the high phosphate-induced HAVICs
calciﬁcation. Spectrophotometric quantiﬁcation of the amount of
released Alizarin Red S dye from the calciﬁed areas conﬁrmed that
the high phosphate-induced HAVICs calciﬁcation was signiﬁcantly
inhibited by MUQ (300 nM, Fig. 3B). No 4
No 5
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p<0.01 p<0.013.2. Gene expression of calciﬁcation markers show MUQ inhibition
of calciﬁcation in HAVICs
We assessed the gene expression of several calciﬁcationmarkers
to identify the intracellular signaling pathway leading to the
inhibitory effect of MUQ on high phosphate-induced HAVICs
calciﬁcation. The gene expression of PiT-1, but not BMP2, was
signiﬁcantly decreased in the presence of MUQ at Day 7 compared
with those in the non-treatment group (Fig. 4A, B). Although MUQ
did not affect the ALP gene expression, it signiﬁcantly inhibited theA
Day 0 Day 7
Pi (3.2 mM) ‒               +                 + ‒
PFA (0.1 mM)     ‒                 ‒             +                 +
No1 No2
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NPs 0         30      300         0         30        300
B
HAVICs
Fig. 2. High phosphate (3.2 mM)-induced calciﬁcation of HAVICs and the inhibitory
effects of the evocarpine derivatives. HAVICs, obtained from patients with CAS, were
cultured in a-MEM containing 10% FBS. After reaching conﬂuence (Day 0), the HAVICs
were further cultured for 7 days (Day 7). (A) Representative images of Alizarin Red S
staining of the high phosphate (3.2 mM)-induced calciﬁcation of HAVICs. Sodium
phosphonoformate (PFA) was used as a selective PiT-1 inhibitor. (B) Representative
Alizarin Red S staining images from two different HAVIC populations. The inhibitory
effect of MUQ, dihydroevocarpine (DHEC), evocarpine (EC), and MNQ on the high
phosphate-induced HAVICs calciﬁcation were assessed.
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Fig. 3. Inhibitory effects of MUQ on high phosphate-induced calciﬁcation of HAVICs.
HAVICs, obtained from patients with CAS, were cultured in a-MEM containing 10% FBS.
After reaching conﬂuence (Day 0), the HAVICs were further cultured for 7 days (Day 7).
(A) Representative images of Alizarin Red S staining from ﬁve different HAVIC pop-
ulations. (B) Quantiﬁcation of the Alizarin Red S staining on Day 7 via extraction with
cetylpyridinium chloride. The amount of released dye was quantiﬁed by spectropho-
tometry at 550 nm. All of the ratios were normalized to the control value on Day 7.
White bar: high phosphate (); blue bar: high phosphate (þ); red bars: high phos-
phate (þ) and MUQ (30e300 nM). Bars represent the mean ± S.E.M. (n ¼ 5).ALP activity, which was increased in the presence of high phos-
phate (Fig. 4C, D).3.3. The inhibitory effects of MUQ on PiT-1 gene expression and ALP
activity compared with those of evocarpine and its other derivatives
To determine the mechanism of MUQ inhibition of high
phosphate-induced HAVICs calciﬁcation, we compared the PiT-1
gene expression and ALP activity of HAVICs after treatment with
MUQ, evocarpine, and the other derivatives. Evocarpine and its
other derivatives in the presence of high phosphate signiﬁcantly
inhibited ALP activity in a similar manner as MUQ (Fig. 5A).
In the absence of high phosphate, MNQ signiﬁcantly decreased
the PiT-1 gene expression. However, in the presence of high
phosphate, none of the other evocarpine derivatives decreased PiT-
1 expression (Fig. 5B). MUQ alone has a tendency to decrease this
gene expression in spite of non-signiﬁcant difference (p ¼ 0.14 vs.
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Fig. 4. Effects of MUQ on the mRNA expression of calciﬁcation-related genes and the ALP activity in HAVICs cultured in high phosphate medium. HAVICs, obtained from patients
with CAS, were cultured in a-MEM containing 10% FBS. After reaching conﬂuence (Day 0), the HAVICs were further cultured in high phosphate medium (3.2 mM) in the presence or
absence of MUQ (300 nM) for 7 days (Day 7). BMP2 (A), PiT-1 (B), and ALP (C) gene expressions in HAVICs were measured on Day 7. All of the ratios were normalized to the control
group on Day 0. The gene expression levels were normalized to the G3PDH gene expression. Bars represent the mean ± S.E.M. (n ¼ 5). (D) ALP activity on Day 7. The cells were
solubilized with 0.5% Triton X-100 in saline, and the supernatants were assayed for ALP activity using a commercially available kit (Laboassay™ ALP). One unit was deﬁned as the
activity producing 1 nmol of p-nitrophenol over 30 min. All of the ratios were normalized to the control group on Day 0. Bars represent the mean ± S.E.M. (n ¼ 5).
K. Seya et al. / Journal of Pharmacological Sciences 131 (2016) 51e57 55high Pi). These results suggest that the inhibitory effect of MUQ on
high phosphate-induced HAVICs calciﬁcation occurs by decreasing
PiT-1 gene expression.
3.4. Western blot analysis of PiT-1 in the presence of MUQ in
HAVICs
To prove the regulatory effect of MUQ on PiT-1 expression in
HAVICs, we further measured the PiT-1 protein expression level on
high phosphate-induced HAVICs calciﬁcation by Western blot
analysis. MUQ signiﬁcantly decreased in the PiT-1 levels in HAVICs
in the presence or absence of high phosphate at Day 7 compared
with that in the high phosphate group (Fig. 6).
4. Discussion
Ectopic calciﬁcation occurs frequently in the aortic valves of CAS
patients. To develop a non-invasive treatment for such calciﬁcation,
such as a drug, it is necessary to ﬁrst elucidate the detailed
mechanism of aortic valve calciﬁcation. Abnormally high serumphosphate levels appear to play an important role in the calciﬁca-
tion process (14). In the present study, exposure to high phosphate
concentrations induced calciﬁcation of the HAVICs at the cellular
level. This calciﬁcation was strongly inhibited by the presence of
PFA, a PiT-1 inhibitor. Further, we conﬁrmed that MUQ, isolated
from the fruits of E. rutaecarpa, inhibited high phosphate-induced
HAVICs calciﬁcation. Finally, we demonstrated that MUQ
decreased not only the gene expression but also cellular protein
level of PiT-1.
There is a report that MUQ inhibits monoamine oxidase B (IC50
value: 15.3 mM) in mouse brain responsible for the oxidative
catabolism of catecholamine which act as neurotransmitters in the
nervous system (26). However, the concentration of MUQ we used
was very low (up to 300 nM) and may not affect the activities of
these monoamine oxidases.
Serum phosphorus levels are normally maintained in the range
of 2.5e4.5 mg/dl. However, in the present study, the mean serum
phosphorus level of the CAS patients (n¼ 6) was high (4.8± 0.4mg/
dL). Inorganic phosphorus is a critical mineral that is mostly found
in bone (85% of total body phosphorus) and is required for high-
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Fig. 5. Effects of MUQ and other evocarpine derivatives on the mRNA expression of
calciﬁcation-related genes and the ALP activity in HAVICs cultured in high phosphate
medium. HAVICs, obtained from patients with CAS, were cultured in a-MEM con-
taining 10% FBS. After reaching conﬂuence (Day 0), the HAVICs were further cultured in
high phosphate medium (3.2 mM) in the presence or absence of MUQ and other
evocarpine derivatives (300 nM) for 7 days (Day 7). (A) ALP activity on Day 7. The cells
were solubilized with 0.5% Triton X-100 in saline, and the supernatants were assayed
for ALP activity using a commercially available kit (Laboassay™ ALP). One unit was
deﬁned as the activity producing 1 nmol of p-nitrophenol over 30 min. All of the ratios
were normalized to the control group on Day 0. Bars represent the mean ± S.E.M.
(n ¼ 5). *: p < 0.05 vs. high phosphate (þ) on Day 7. (B) PiT-1 gene expression in
HAVICs was measured on Day 7. All of the ratios were normalized to the control group
on Day 0. The gene expression levels were normalized to the G3PDH gene expression.
Bars represent the mean ± S.E.M. (n ¼ 5). *: p < 0.05 vs. high phosphate (þ) at Day 7. #:
P < 0.05 vs. control at Day 7.
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Fig. 6. Effects of MUQ on the PiT-1 protein expression of calciﬁcation-related genes in
HAVICs cultured in high phosphate medium. HAVICs, obtained from patients with CAS,
were cultured in a-MEM containing 10% FBS. After reaching conﬂuence, the HAVICs
were further cultured in high phosphate medium (3.2 mM) in the presence or absence
of MUQ (300 nM) for 7 days (Day 7). PiT-1 protein expression in HAVICs was measured
on Day 7. All of the ratios were normalized to the control group on Day 7. The protein
expression levels were normalized to the b-actin protein expression. Lane 1, non-
treatment (control); lane 2, high phosphate (3.2 mM); lane 3, MUQ (300 nM); lane
4, high phosphate (3.2 mM) in the presence of MUQ (300 nM). Bars represent the
mean ± S.E.M. (n ¼ 5).
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(27). The kidney is the major regulator of phosphate homeostasis,
whereby 70% of phosphate reabsorption in the proximal convo-
luted tubule occurs via a sodium-dependent phosphate cotrans-
porter. Two other phosphate transporters, PiT-1 and PiT-2, also
contribute to renal phosphate reabsorption (28). In general, high
phosphorus levels mainly induce cell calciﬁcation via the activation
of Pit-1 (29), which is also supported by our present results. Further,
we conﬁrmed that MUQ did not affect the PiT-2 gene expression (K.
Seya et al., unpublished data). Thus, the inhibition of PiT-1 activity
is useful for preventing ectopic calciﬁcation caused by
hyperphosphatemia.
The pharmacological effects of MUQ on HAVICs include not only
the inhibition of PiT-1, but also of ALP activity. ALP is well-knownfor its contributions to aortic valve calciﬁcation. However, ALP
gene expression was not affected by MUQ, and neither was the
expression of BMP2, an important upstream factor for ALP. Further,
although evocarpine and its derivatives except MUQ also inhibited
the high phosphate-induced increase in ALP activity, they did not
mitigate the high phosphate-induced HAVICs calciﬁcation. In
another study, MUQ did not inhibit the TNF-a-induced calciﬁcation
of HAVICs via BMP2-ALP signaling (data not shown). Thus, the high
phosphate-induced ALP activation may be caused by a compensa-
tory reaction andmay not contribute to the HAVICs calciﬁcation. On
the other hand, in the high phosphate condition, none of these
compounds besides MUQ altered the PiT-1 gene expression. These
results suggest that the inhibitory effects of MUQ on high
phosphate-induced HAVICs calciﬁcation are driven by the sup-
pression of inorganic phosphate uptake into HAVICs via PiT-1.
Although MNQ alone decreased the PiT-1 gene expression, this
effect may be weak in the presence of high phosphate.
Unlike MUQ, the gene expression of PiT-1 by HAVICs was not
decreased by evocarpine or its other derivatives. However, these
observations do not explainwhyMUQ, but not the other compounds,
decreases the PiT-1 gene expression in HAVICs. The structural dif-
ferences between MUQ and the other evocarpine derivatives are
limited to functional groups at the 2-position. Imramovsky et al.
reported that the acetylcholinesterase-inhibiting activity of salicy-
lanilide N-alkylcarbamates was largely varied depending on the side
chain (30). In the present study, the undecyl group of theMUQ at the
2-position may affect the expression of the PiT-1 gene. However,
further study of the role of the undecyl group at the 2-position of
MUQ is needed to clarify the molecular mechanism of the inhibition
of high phosphate-induced HAVICs calciﬁcation.
No effective drugs have been identiﬁed that inhibit the ectopic
calciﬁcation of aortic valve (31). Son et al. reported that statins
K. Seya et al. / Journal of Pharmacological Sciences 131 (2016) 51e57 57protected human aortic smooth muscle cells and HAVICs from
phosphate-induced calciﬁcation by inhibiting apoptosis via resto-
ration of the Gas6-Axl pathway (32). However, a critique of the
results of the “JUPITER trial” (REF) stated that the results of the trial
did not support the use of statins for the primary prevention of
cardiovascular diseases and raised troubling questions concerning
the role of commercial sponsors (33). Further, simvastatin and
ezetimibe did not reduce the composite outcome of combined
aortic valve events and ischemic events in patients with aortic
stenosis. These therapies reduced the incidence of ischemic car-
diovascular events, but not the incidence of events related to aortic
valve stenosis (34). The results of the present study suggest that
MUQ may be a candidate for development as a new medical entity
that can inhibit ectopic calciﬁcation in aortic stenosis caused by
hyperphosphatemia.
One limitation of the present study is that the detailed molec-
ular mechanism of the action of MUQ was not elucidated. Although
PFA inhibits PiT-1 activity at the experimental level, its molecular
mechanism has also not yet been elucidated (35). In future studies,
we should analyze the structure-activity relationships among MUQ
and other evocarpine derivatives and the biophysical interactions
between MUQ and PiT-1. That information will allow us to develop
a more active compound through chemical modiﬁcation of the
quinolone alkyl group of MUQ.
In conclusion, we demonstrated that MUQ (30e300 nM), iso-
lated from the fruits of E. rutaecarpa, inhibited high phosphate
(3.2 mM)-induced HAVICs calciﬁcation in a concentration-
dependent manner. We also showed that the inhibitory effect of
MUQ is caused by the attenuation of both gene expression and
cellular protein level of PiT-1. We hope that these results will help
to clarify the molecular mechanism of the inhibitory effect of MUQ
and assist the development of new therapies for ectopic calciﬁca-
tion in aortic stenosis.
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